Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: A meta-analysis of observational studies

Blood

Volumn 119, Issue 21, 2012, Pages 4845-4850

  Castillo, Jorge J ^a   Mull, Nikhil ^a   Reagan, John L ^a   Nemr, Saed ^a   Mitri, Joanna ^b  

^a BROWN UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RISK; COCHRANE LIBRARY; DISEASE ASSOCIATION; HUMAN; LEUKEMIA; MEDLINE; MULTIPLE MYELOMA; MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW;

EID: 84861494765     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-362830     Document Type: Article

References (45)

1. Surveillance Epidemiology and End Results. Available from: http://seer.cancer.gov/statfacts/ index.html. Accessed January 31, 2012.
2. National Diabetes Information Clearinghouse. Available from: http://diabetes.niddk.nih.gov/ dm/pubs/statistics/index.htm. Accessed January 31, 2012.
3. Mitri J, Castillo J, Pittas AG. Diabetes and risk of non-Hodgkin's lymphoma: a meta-analysis of observational studies. Diabetes Care. 2008;31(12): 2391-2397.
4. Stroup DF, Berlin JA, Morton SC, et al. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008- 2012.
5. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Available from: http://www.ohri.ca/ programs/clinical-epidemiology/oxford.asp. Accessed January 31, 2012.
6. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19): 1690-1691. (Pubitemid 28532993)
7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. (Pubitemid 17189972)
8. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11): 1539-1558. (Pubitemid 34746062)
9. Duval S, Tweedie R. Trim and fill: A simple funnelplot- based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-463. (Pubitemid 30422636)
10. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer. 2011;128(3):635-643.
11. Cerhan JR, Wallace RB, Folsom AR, et al. Medical history risk factors for non-Hodgkin's lymphoma in older women. J Natl Cancer Inst. 1997; 89(4):314-318. (Pubitemid 27085894)
12. Erber E, Lim U, Maskarinec G, Kolonel LN. Common immune-related risk factors and incident non-Hodgkin lymphoma: the multiethnic cohort. Int J Cancer. 2009;125(6):1440-1445.
13. Hemminki K, Li X, Sundquist J, Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist. 2010;15(6):548-555.
14. Hjalgrim H, Frisch M, Ekbom A, Kyvik KO, Melbye M, Green A. Cancer and diabetes-a follow- up study of two population-based cohorts of diabetic patients. J Intern Med. 1997;241(6):471- 475.
15. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293(2): 194-202. (Pubitemid 40095870)
16. Khan AE, Gallo V, Linseisen J, et al. Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition. Haematologica. 2008;93(6):842-850. (Pubitemid 351821720)
17. Khan M, Mori M, Fujino Y, et al. Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. Asian Pac J Cancer Prev. 2006;7(2):253- 259.
18. Ogunleye AA, Ogston SA, Morris AD, Evans JM. A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer. 2009;101(7): 1199-1201.
19. Ragozzino M, Melton LJ, 3rd Chu CP, Palumbo PJ. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis. 1982;35(1): 13-19. (Pubitemid 12213476)
20. Swerdlow AJ, Laing SP, Qiao Z, et al. Cancer incidence and mortality in patients with insulintreated diabetes: a UK cohort study. Br J Cancer. 2005;92(11):2070-2075. (Pubitemid 40897432)
21. Weiderpass E, Gridley G, Ekbom A, Nyren O, Hjalgrim H, Adami HO. Medical history risk factors for non-Hodgkin's lymphoma in older women. J Natl Cancer Inst. 1997;89(11):816-817.
22. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89(18):1360- 1365.
23. Boffetta P, Stellman SD, Garfinkel L. A casecontrol study of multiple myeloma nested in the American Cancer Society prospective study. Int J Cancer. 1989;43(4):554-559. (Pubitemid 19110086)
24. Cartwright RA, Bernard SM, Bird CC, et al. Chronic lymphocytic leukaemia: case control epidemiological study in Yorkshire. Br J Cancer. 1987;56(1):79-82. (Pubitemid 17097704)
25. Cartwright RA, McKinney PA, O'Brien C, et al. Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire. Leuk Res. 1988; 12(1):81-88.
26. Cerhan JR, Bernstein L, Severson RK, et al. Anthropometrics, physical activity, related medical conditions, and the risk of non-Hodgkin lymphoma. Cancer Causes Control. 2005;16(10): 1203-1214. (Pubitemid 46187570)
27. Fortuny J, Benavente Y, Bosch R, Garcia-Villanueva M, de Sevilla AF, de Sanjose S. Type 2 diabetes mellitus, its treatment and risk for lymphoma. Eur J Cancer. 2005;41(12):1782- 1787.
28. Holly EA, Bracci PM. Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virusnegative participants in San Francisco. Am J Epidemiol. 2003;158(4):316-327. (Pubitemid 41288799)
29. Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev. 2007;16(1): 83-89. (Pubitemid 46105011)
30. Lin SY, Hsieh MS, Chen LS, Chiu YH, Yen AM, Chen TH. Diabetes mellitus associated with the occurrence and prognosis of non-Hodgkin's lymphoma. Eur J Cancer Prev. 2007;16(5):471-478. (Pubitemid 47550009)
31. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer. 2006; 118(8):2105-2109.
32. Scotti L, Tavani A, Bosetti C, et al. Diabetes and risk of non-Hodgkin lymphoma: a case-control study. Tumori. 2007;93(1):1-3. (Pubitemid 46506521)
33. Vineis P, Crosignani P, Sacerdote C, et al. Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Community Health. 2000;54(6):431-436. (Pubitemid 30312519)
34. Wotton CJ, Yeates DG, Goldacre MJ. Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia. 2011;54(3):527-534.
35. Zahm SH, Blair A, Cantor KP, Fraumeni JF Jr. Non-insulin dependent diabetes mellitus and non- Hodgkin's lymphoma. Other American studies fail to confirm an association. BMJ. 1995;310(6985): 1009-1010.
36. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60(4):207-221.
37. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371(9612):569-578. (Pubitemid 351232031)
38. Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab. 1992;18(3):187-201.
39. Handwerger BS, Fernandes G, Brown DM. Immune and autoimmune aspects of diabetes mellitus. Hum Pathol. 1980;11(4):338-352. (Pubitemid 10032505)
40. Cheung MC, Pantanowitz L, Dezube BJ. AIDSrelated malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist. 2005;10(6):412-426. (Pubitemid 40993569)
41. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165(20):2337-2344. (Pubitemid 41640845)
42. Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer. 2009;125(2):398-405.
43. Ekström Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111(8): 4029-4038.
44. Jagannathan-Bogdan M, McDonnell ME, Shin H, et al. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol. 2011;186:1162-1172.
45. Margolis KL, Lihong Q, Brzyski R, et al. Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials. 2008;5(3):240-247.